This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The Hormone Assay Core Lab was the first component of the CRC to be developed following funding. The objective of the Hormone Assay Core Lab is to expand the hormone assay capabilities at Charles Drew University by developing and making available hormone measurement methods not currently available to the investigators. The Hormone Assay Core Laboratory has had considerable success in refining existing assays to meet specific needs of investigators, and in developing new assays. Below is a list of hormone assays that are currently available: 1. Serum LH: A 2-site directed fluoroimmunometric assay (FIA). 2. Serum FSH: A 2-site directed fluoroimmunometric assay (FIA). 3. Testosterone: The assay for testosterone uses an iodinated tracer and extraction of serum samples using anexane: ethyl acetate (2:3) mixture, prior to immunoassay. The laboratory has published the development of a highly sensitive testosterone assay that has been optimized for the measurement of low testosterone levels in women. 4. Free Testosterone: Free testosterone levels are measured by a direct equilibrium dialysis procedure. The laboratory has published the development and validation of the sensitive assay for the measurement of low free testosterone levels in women, and the generation of normative data in menstruating women. 5. Dihydrotestosterone: Serum samples are extracted and chromatographed through a Celite column. DHT concentrations are measured in the eluate from the Celite fractions by RIA. 6. Sex-Hormone Building Globulin (SHBG): Serum SHBG binding capacity is measured by using tracer amounts of [3H-DHT] and serial dilutions of DHT standards. 7. Insulin: Insulin assay uses a standard from Wellcome equated to 1st 1RP GG/304, antiporcine antibody from ICN and porcine insulin from Lilly for iodination. 8. C-Peptide: C-Peptide assay uses antisera, standards and iodination material supplied through the Eli Lilly Company and an ethanol separation technique. Androstenedione, DHEA, Estrone, estradiol, myostatin, inflammatory markers, C-reactive protein and IL-6. 9. Since its initial funding, the HAC Lab has provided state-of-the-art service, and has been highly innovative in developing new assays. The HAC Lab has encouraged collaborations between molecular biologists and clinical investigators. The HAC Lab has had an outstanding record of accomplishments;it has supported a large number of high-impact, peer-reviewed publications, and new RO1 grant applications. Note: The Core does not conduct any studies of it''s own. It provides hormone measurements to studies that are CRC and IRB approved. Therefore, it uses the same IRB approval as the umbrella CRC grant does. There is no patient enrollment by the Core. It is purely a hormone measurement laboratory.

Agency
National Institute of Health (NIH)
Institute
National Center for Research Resources (NCRR)
Type
Exploratory Grants (P20)
Project #
3P20RR011145-14S2
Application #
7960748
Study Section
National Center for Research Resources Initial Review Group (RIRG)
Project Start
2009-09-25
Project End
2009-09-30
Budget Start
2009-09-25
Budget End
2009-09-30
Support Year
14
Fiscal Year
2009
Total Cost
$39,924
Indirect Cost
Name
Charles R. Drew University of Medicine & Science
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
785877408
City
Los Angeles
State
CA
Country
United States
Zip Code
90059
Grams, Morgan E; Sang, Yingying; Ballew, Shoshana H et al. (2018) Predicting timing of clinical outcomes in patients with chronic kidney disease and severely decreased glomerular filtration rate. Kidney Int 93:1442-1451
Inker, Lesley A; Grams, Morgan E; Levey, Andrew S et al. (2018) Relationship of Estimated GFR and Albuminuria to Concurrent Laboratory Abnormalities: An Individual Participant Data Meta-analysis in a Global Consortium. Am J Kidney Dis :
Juraschek, Stephen P; Miller 3rd, Edgar R; Appel, Lawrence J (2018) Orthostatic Hypotension and Symptoms in the AASK Trial. Am J Hypertens 31:665-671
Chen, Teresa K; Appel, Lawrence J; Grams, Morgan E et al. (2017) APOL1 Risk Variants and Cardiovascular Disease: Results From the AASK (African American Study of Kidney Disease and Hypertension). Arterioscler Thromb Vasc Biol 37:1765-1769
Juraschek, Stephen P; Appel, Lawrence J; Miller 3rd, Edgar R (2017) Metoprolol Increases Uric Acid and Risk of Gout in African Americans With Chronic Kidney Disease Attributed to Hypertension. Am J Hypertens 30:871-875
Chen, Teresa K; Tin, Adrienne; Peralta, Carmen A et al. (2017) APOL1 Risk Variants, Incident Proteinuria, and Subsequent eGFR Decline in Blacks with Hypertension-Attributed CKD. Clin J Am Soc Nephrol 12:1771-1777
Liang, Su; Bian, Xiaomei; Liang, Dong et al. (2016) Solution formulation development and efficacy of MJC13 in a preclinical model of castration-resistant prostate cancer. Pharm Dev Technol 21:121-6
Chen, Teresa K; Choi, Michael J; Kao, W H Linda et al. (2015) Examination of Potential Modifiers of the Association of APOL1 Alleles with CKD Progression. Clin J Am Soc Nephrol 10:2128-35
Chen, Teresa K; Estrella, Michelle M; Astor, Brad C et al. (2015) Longitudinal changes in hematocrit in hypertensive chronic kidney disease: results from the African-American Study of Kidney Disease and Hypertension (AASK). Nephrol Dial Transplant 30:1329-35
Chang, Alex; Greene, Tom H; Wang, Xuelei et al. (2015) The effects of weight change on glomerular filtration rate. Nephrol Dial Transplant 30:1870-7

Showing the most recent 10 out of 146 publications